- Home
- FMY vs ACRV Comparison
FMY vs ACRV Comparison
Compare FMY & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FMY
- ACRV
- Stock Information
- Founded
- FMY 2005
- ACRV 2018
- Country
- FMY United States
- ACRV United States
- Employees
- FMY N/A
- ACRV N/A
- Industry
- FMY Finance/Investors Services
- ACRV Medicinal Chemicals and Botanical Products
- Sector
- FMY Finance
- ACRV Health Care
- Exchange
- FMY Nasdaq
- ACRV Nasdaq
- Market Cap
- FMY 50.5M
- ACRV 40.4M
- IPO Year
- FMY N/A
- ACRV 2022
- Fundamental
- Price
- FMY $12.19
- ACRV $1.43
- Analyst Decision
- FMY
- ACRV Buy
- Analyst Count
- FMY 0
- ACRV 7
- Target Price
- FMY N/A
- ACRV $17.60
- AVG Volume (30 Days)
- FMY 10.1K
- ACRV 371.9K
- Earning Date
- FMY 01-01-0001
- ACRV 08-12-2025
- Dividend Yield
- FMY 6.98%
- ACRV N/A
- EPS Growth
- FMY N/A
- ACRV N/A
- EPS
- FMY N/A
- ACRV N/A
- Revenue
- FMY N/A
- ACRV N/A
- Revenue This Year
- FMY N/A
- ACRV N/A
- Revenue Next Year
- FMY N/A
- ACRV N/A
- P/E Ratio
- FMY N/A
- ACRV N/A
- Revenue Growth
- FMY N/A
- ACRV N/A
- 52 Week Low
- FMY $10.71
- ACRV $1.05
- 52 Week High
- FMY $12.17
- ACRV $10.16
- Technical
- Relative Strength Index (RSI)
- FMY 51.72
- ACRV 59.53
- Support Level
- FMY $12.19
- ACRV $1.34
- Resistance Level
- FMY $12.28
- ACRV $1.50
- Average True Range (ATR)
- FMY 0.06
- ACRV 0.08
- MACD
- FMY -0.01
- ACRV 0.01
- Stochastic Oscillator
- FMY 43.48
- ACRV 74.07
About FMY First Trust Motgage Income Fund of Beneficial Interest
First Trust Mortgage Income Fund is a United States based diversified, closed-end management investment company. The fund's primary investment objective is to seek a high level of current income. Its secondary investment objective is to preserve capital. The fund pursues its objectives by investing predominantly in mortgage-backed securities representing part ownership in a pool of either residential or commercial mortgage loans that, in the opinion of the Fund's investment advisor, offer an attractive combination of credit quality, yield and maturity.
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.